Cas:936822-38-7 Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy] manufacturer & supplier

Chemical Name:Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy]

CAS.NO:936822-38-7

Synonyms:4-((3,5-Dimethylisoxazol-4-yl)methoxy)benzene-1-sulfonyl chloride

Molecular Formula:C₁₂H₁₂ClNO₄S

Molecular Weight:301.74600

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:472.6±40.0 °C (760 mmHg)

Density:1.375±0.06 g/cm3 (20 °C, 760 mmHg)

Index of Refraction:

PSA:77.78000

Exact Mass:301.01800

LogP:3.87870

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-((3,5-Dimethylisoxazol-4-yl)methoxy)benzene-1-sulfonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-((3,5-Dimethylisoxazol-4-yl)methoxy)benzene-1-sulfonyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-((3,5-Dimethylisoxazol-4-yl)methoxy)benzene-1-sulfonyl chloride Use and application,4-((3,5-Dimethylisoxazol-4-yl)methoxy)benzene-1-sulfonyl chloride technical grade,usp/ep/jp grade.

Related News: Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy] manufacturer Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy] supplier Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy] vendor Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. Benzenesulfonyl chloride, 4-[(3,5-dimethyl-4-isoxazolyl)methoxy] factory Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.